AN2 Therapeutics Phase 3 Trial Pause Impacts Stock
AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...
- Latest
- Trending
AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...
FDA approves Takeda's EOHILIA as first-line treatment for Eosinophilic Esophagitis. Groundbreaking oral therapy offers hope for improved quality of life.
Deutsche Bank reiterates Buy rating on Select Medical Holdings Corporation, stating the market is undervaluing the stock & predicting significant ...
Anixa Biosciences advances Phase 1 clinical trial for ovarian cancer therapy, increasing dosage and showing promising results. Market responds positively ...
Kintara Therapeutics has launched a clinical trial for REM-001, a promising treatment for cutaneous metastatic breast cancer. The trial aims ...
Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
Cidara Therapeutics receives $11.1 million milestone payment from Mundipharma for European approval of new antifungal drug, Rezzayo. Analysts see potential ...
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
Sharp HealthCare is leading the way in bringing Apple's Vision Pro VR headset into healthcare. The high-resolution screens and advanced ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.